Anúncio
Anúncio

MLTX

MLTX logo

MoonLake Immunotherapeutics Class A Ordinary Shares

18.52
USD
Patrocinado
+4.18
+29.11%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

19.35

+0.83
+4.49%

Relatórios de Lucros MLTX

Rácio de surpresa positiva

MLTX separação 8 de 14 últimas estimativas.

57%

Próximo Relatório

Data do Próximo Relatório
24 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$1.00
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
-9.09%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
+38.89%

MoonLake Immunotherapeutics Class A Ordinary Shares earnings per share and revenue

On 05 de nov. de 2025, MLTX reported earnings of -1.10 USD per share (EPS) for Q3 25, missing the estimate of -0.89 USD, resulting in a -22.75% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analistas forecast an EPS of -1.00 USD, with revenue projected to reach -- USD, implying an diminuir of -9.09% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, MoonLake Immunotherapeutics Class A Ordinary Shares reported EPS of -$1.10, missing estimates by -22.75%, and revenue of $0.00, 0% as expectations.
The stock price moved up 4.54%, changed from $10.13 before the earnings release to $10.59 the day after.
The next earning report is scheduled for 24 de fev. de 2026.
Based on 18 analistas, MoonLake Immunotherapeutics Class A Ordinary Shares is expected to report EPS of -$1.00 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio